N-羟基-2-[[[（4-甲氧基苯基）磺酰基]（2-甲基丙基）氨基]乙酰胺 | 161314-17-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-羟基-2-[[[（4-甲氧基苯基）磺酰基]（2-甲基丙基）氨基]乙酰胺
• 英文名称: N-hydroxy-2-[isobutyl-(4-methoxybenzenesulfonyl)amino]acetamide
• 英文别名: NNGH；N-isobutyl-N-(4-methoxyphenylsulfonyl)glycyl hydroxamic acid；N-Hydroxy-2-[[4-methoxybenzenesulfonyl](isobutyl)-amino]acetamide；N-Isobutyl-N-[4-methoxyphenylsulfonyl]glycyl hydroxamic acid；N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-(2-methylpropyl)amino]acetamide
• CAS: 161314-17-6
• 化学式: C₁₃H₂₀N₂O₅S
• 分子量: 316.378
• InChiKey: JIRXORZYIXSWOB-UHFFFAOYSA-N

物化性质

• 熔点：
  125-126 °C
• 密度：
  1.271±0.06 g/cm3(Predicted)
• 溶解度：
  DMSO：可溶15mg/mL，澄清

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  对甲氧基苯磺酰氯 在 盐酸羟胺 、 sodium methylate 、 sodium hydride 、 三乙胺 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 2.5h， 生成 N-羟基-2-[[[（4-甲氧基苯基）磺酰基]（2-甲基丙基）氨基]乙酰胺
  参考文献：
  名称：

  Discovery of CGS 27023A, a Non-Peptidic, Potent, and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in Rabbits

  摘要：

  Structure-activity relationships of a lead hydroxamic acid inhibitor of recombinant human stromelysin were systematically defined by taking advantage of a concise synthesis that allowed diverse functionality to be explored at each position in a template. An ex vivo rat model and an in vivo rabbit model of stromelysin-induced cartilage degradation were used to further optimize these analogs for oral activity and duration of action. The culmination of these modifications resulted in CGS 27023A, a potent, orally active stromelysin inhibitor that blocks the erosion of cartilage matrix.

  DOI：

  10.1021/jm960871c

文献信息

• Hydroxamates: Relationships between Structure and Plasma Stability
  作者：Marion Flipo、Julie Charton、Akila Hocine、Sandrine Dassonneville、Benoit Deprez、Rebecca Deprez-Poulain

  DOI：10.1021/jm900648x

  日期：2009.11.12

  display nanomolar activities against metalloproteases, only three hydroxamates have reached the market, among which is the HDAC inhibitor vorinostat. Failures in development are generally attributed to lack of selectivity, toxicity, or poor stability. To help medicinal chemists with respect to plasma stability, we have performed the first and preliminary study on structure−plasma stability for hydroxamates

  异羟肟酸酯是用于化学生物学的有价值的工具，也是用于药物化学的有趣线索。尽管许多异羟肟酸酯显示出对金属蛋白酶的纳摩尔活性，但只有三种异羟肟酸酯进入市场，其中包括HDAC抑制剂伏立诺他。开发失败通常归因于缺乏选择性，毒性或稳定性差。为了帮助药用化学家进行血浆稳定性方面的研究，我们对异羟肟酸酯的结构-血浆稳定性进行了首次和初步研究。我们定义一些结构规则，以预测或改善临床前阶段的血浆稳定性。
• [EN] SELENOPHENOCHROMENE HYDROXAMIC ACIDS, PREPARATION AND USE AS ANGIOGENESIS INHIBITORS<br/>[FR] ACIDES HYDROXAMIQUES DE SÉLÉNOPHÉNOCHROMÈNE, LEUR PRÉPARATION ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE L'ANGIOGENÈSE
  申请人：LATVIAN INST ORGANIC SYNTHESIS

  公开号：WO2020053639A1

  公开（公告）日：2020-03-19

  The present invention relates to a novel selenophenochromene hydroxamic acids as angiogenesis inhibitors, as well as methods of their manufacturing and use in different pharmaceutical compositions for the treatment or prevention of various diseases and disorders by administration of such substances.

  本发明涉及一种新型硒苯基色素羟肟酸作为血管生成抑制剂，以及它们的制造方法和在不同药物组合中的使用，用于通过给予这些物质来治疗或预防各种疾病和紊乱。
• Novel method of treatment of inflammatory skin conditions
  申请人：Chandler Rupert Stephen

  公开号：US20070049518A1

  公开（公告）日：2007-03-01

  There is provided, inter alia, a method for the treatment or prevention of an inflammatory skin condition which is characterised by colonisation with Staphylococcus aureus , comprising the topical administration of an aureolysin inhibitor.

  提供了一种治疗或预防由金黄色葡萄球菌定植引起的炎症性皮肤病的方法，包括局部施用一种金黄色葡萄球菌溶素抑制剂。
• Homogenous assay for enzymatic activity
  申请人：Savage Dean M.

  公开号：US20050106655A1

  公开（公告）日：2005-05-19

  An assay is disclosed for measuring activity of enzymes, such as kinases, phosphatases, and proteases. Measurements of enzymatic activity are accomplished in a homogenous assay format utilizing a fluorescence quenching technique employing paramagnetic metal ions.

  本发明公开了一种用于测量酶活性的测定方法，例如激酶、磷酸酶和蛋白酶。采用荧光猝灭技术和顺磁金属离子进行均相测定，以实现酶活性的测量。
• Statin-MMP inhibitor combinations
  申请人：——

  公开号：US20020049237A1

  公开（公告）日：2002-04-25

  The invention is a pharmaceutical composition comprising an MMP inhibitor and a statin, said composition being useful for treating vascular diseases.

  这项发明是一种药物组合物，包括MMP抑制剂和他汀类药物，该组合物可用于治疗血管疾病。